TRPM8
ENSG00000144481
Target class
Ion channel
Chromosome
2
Approved drugs
1
Clinical candidates (approved and in development)
3
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 3
- Chemical probe available
- Yes
- Target name
- TRPM8
- Gene name
- Transient receptor potential cation channel subfamily M member 8
- Gene symbol
- TRPM8
- Protein name
- Transient receptor potential cation channel subfamily M member 8 (Long transient receptor potential channel 6) (LTrpC-6) (LTrpC6) (Transient receptor potential p8) (Trp-p8)
- Gene biotype
- Protein coding
- Gene family
- Transient receptor potential cation channels
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 2
- Highest tissue expression
- 14.1
- Tissue specificity (Gini)
- 0.944
- Tissue specificity (tau)
- 0.987
- KEGG gene identifiers
- hsa:79054
- Reactome pathways
- R-HSA-3295583
- Protein interaction confidence
- 0.850111
- Protein interaction partners
- 18
- End position
- 234019522
- Start position
- 233917373
- Chromosome
- 2
- Strand
- Forward
- Cell membrane
- Multi-pass membrane protein . Membrane raft . Endoplasmic reticulum membrane . Note=Lipid raft association modulates TRPM8 channel activity (By similarity). Located in the endoplasmic reticulum in prostate cancer cells (PubMed:11325849, PubMed:16174775). .
- PubMed 16174775
- PubMed 37857704
- PubMed 11325849
- Tissue specificity (tau)
- 0.987127
- Expression inequality (Gini)
- 0.944351
Expression in transcripts per million
- Prostate
- 14.1
- Liver
- 7.65
- Testis
- 0.72
- Pituitary
- 0.27
- Brain - Hypothalamus
- 0.11
Expression in transcripts per million
- Prostate14.1
- Liver7.65
- Testis0.72
- Pituitary0.27
- Brain - Hypothalamus0.11
- Brain - Caudate (basal ganglia)0.08
- Brain - Putamen (basal ganglia)0.07
- Brain - Cerebellum0.06
- Brain - Cerebellar Hemisphere0.05
- Brain - Substantia nigra0.04
- Brain - Nucleus accumbens (basal ganglia)0.04
- Kidney - Cortex0.04
- Spleen0.04
- Skin - Sun Exposed (Lower leg)0.03
- Brain - Frontal Cortex (BA9)0.03
- Brain - Spinal cord (cervical c-1)0.03
- Pancreas0.03
- Minor Salivary Gland0.03
- Vagina0.03
- Brain - Anterior cingulate cortex (BA24)0.03
- Cervix - Endocervix0.02
- Brain - Cortex0.02
- Brain - Amygdala0.02
- Cervix - Ectocervix0.02
- Breast - Mammary Tissue0.01
And 29 more, listed on the interactive page.
Biological processes
- GO:0070588
- GO:0005789
- GO:0005886
- GO:0005262
- GO:0005515
Related records
Trials (49)
- A Local Clinical Study for the Comparative Evaluation of Efficacy and Safety of Angal, Lozenges [Menthol] and ANTI-ANGIN® FORMULA, Lozenges, in Treatment of Patients With a Sore Throat
- A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
- A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
- A Phase IIb, Randomized, Double-Blind, Placebo-Controlled Study of Elismetrep (K-304) in the Treatment of Migraine
- A Safety Study to Investigate the Skin Irritancy Potential of Diclofenac-Menthol Gel
- A Safety Study to Investigate the Skin Sensitization Potential of MFC51123
- A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
- A Study to Evaluate the Efficacy and Safety of K-285 Compared With Menthol Gel for the Treatment of Delayed Onset Muscle Soreness (DOMS) in the Lower Extremity
- A Study to Investigate the Effect of MT-8554 on the Pharmacokinetics of Simvastatin and Rosuvastatin in Healthy Subjects
- A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjects
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects
- A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
- Analgesic Induces Similar Upper and Lower Body Pain Pressure Threshold Increases
- Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model
- Clinical Adhesion Study Between ZTlido 1.8% and Three Over-the-counter External Analgesic Lidocaine-containing Patches
- Clinical Study for Comparative Assessment of Efficacy and Safety of Angal S, Topical Spray and ANTI-ANGIN® FORMULA, Topical Metered Spray in Treatment of Patients With Uncomplicated Acute Infectious and Inflammatory Diseases of the Pharynx, Accompanied by a Sore Throat
- Comparative Efficacy of the Suppository Versus Guaiacol Suppository Versus Guaifenesin Syrup in Pediatric Patients With Cough Due the Infectious Origin
- Comparison of Prescription Lidocaine Patch to Over the Counter Lidocaine Patch and Placebo for Back Pain and Arthritis
- Definitive QT Study With MT-8554
- Dose Escalation Study of EC D-3263 HCl in Advanced Solid Tumors
Drugs (3)
- D-3263 Transient receptor potential cation channel subfamily M member 8 agonist
- Elismetrep Transient receptor potential cation channel subfamily M member 8 inhibitor
- Menthol Transient receptor potential cation channel subfamily M member 8 opener